Clinical Trials Logo

Filter by:
NCT ID: NCT05609630 Recruiting - Clinical trials for Juvenile Idiopathic Arthritis

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

SELECT-sJIA
Start date: October 2, 2023
Phase: Phase 3
Study type: Interventional

Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin". It is a chronic (long-lasting) disease that causes swelling, warmth, and pain of one or more small joints. Systemic JIA ia a rare and serious form of JIA. Systemic" means it may affect not only the joints but other parts of the body, including the liver, lungs and heart. sJIA is more severe and can be more challenging to diagnose and treat than other types of juvenile idiopathic arthritis. It is a lifelong disease for many patients and can continue into adulthood. This study will assess how safe and effective upadacitinib is in treating pediatric and adolescent participants aged 1 to < 18 with systemic juvenile idiopathic arthritis (sJIA) and will include a tocilizumab treatment arm for reference. Adverse events and change in the disease activity will be assessed. Upadacitinib is an investigational drug being developed for the treatment of sJIA. Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive upadacitinib or tocilizumab reference. In cohort 2, participants will receive upadacitinib. Approximately 90 participants with sJIA will be enrolled in approximately 45 sites worldwide. Participants will receive upadacitinib oral tablets once daily or oral solution twice daily or tocilizumab subcutaneous injection or intravenous infusion as per local label for 52 weeks and followed for approximately 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits/calls during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

NCT ID: NCT05609591 Recruiting - Bowel Preparation Clinical Trials

Three Dietary Regimens in Pre-colonoscopic Bowel Preparation in Children

Start date: November 9, 2022
Phase: N/A
Study type: Interventional

To describe the feasibility and effectiveness of three dietary regimens in precolonoscopy bowel preparation in children

NCT ID: NCT05609383 Withdrawn - Evaluation Clinical Trials

Out-patient Discharge Management After General Intravenous Anesthesia

Start date: October 20, 2022
Phase:
Study type: Observational

The lower limit of time for postoperative observation and discharge criteria for diagnostic or operational tests program in outpatient under general intervenous anesthesia/sedation

NCT ID: NCT05609370 Recruiting - Clinical trials for Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Start date: January 29, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine to participants with colorectal cancer.

NCT ID: NCT05609162 Enrolling by invitation - Brain Metastases Clinical Trials

Treatments for Brain Metastases With Poor Prognostic Factors

TBMPPF
Start date: December 15, 2022
Phase:
Study type: Observational

The goal of this observational study is to learn about treatments in brain metastases with poor prognostic factors. The main questions it aims to answer are: - What kind of local treatment provides a survival benefit for patients with poor prognostic factors? - What kind of systemic treatment provides a survival benefit for patients with poor prognostic factors? - Will the combination of local treatment and systemic treatment provide a survival benefit for patients with poor prognostic factors? Participants will be asked to provide personal information about their living status, symptoms, and disease control during the follow-up.

NCT ID: NCT05609149 Completed - Rectal Cancer Clinical Trials

MRI Features in Neoadjuvant Treatment Decisions for Patients With Rectal Cancer

Start date: October 30, 2016
Phase:
Study type: Observational

This study investigates whether risk criteria based on MRI features could identify a cohort of patients with a good prognosis among those recommended for preoperative treatment by NCCN guidelines to avoid preoperative treatment with the likely good survival outcomes by primary surgery and more accurately indicate the response to the treatment and predict prognosis after neoadjuvant treatmen than radiographic TNM staging in the patients who received neoadjuvant therapy.

NCT ID: NCT05609110 Recruiting - Clinical trials for Intracranial Hemorrhages

Safety and Efficacy of Remote Ischemic Conditioning for Spontaneous Intracerebral Hemorrhage

Start date: February 2, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning in treating acute intracerebral hemorrhage.

NCT ID: NCT05609058 Recruiting - Breast Cancer Clinical Trials

The Influence of Treatment Position (Prone vs. Supine) on Whole Breast Target

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Radiotherapy after breast conserving therapy plays an important role in early stage breast cancer patients. It not only results in a reduction in local and regional recurrence but also decrease the death rate effectively. For adjuvant radiotherapy, supine positioning is the most common approach and has multiple advantages. Due to deformability and softness of the breast, during simulation and treatment in supine position, the breast stretches over the chest wall, especially in patients with large and pendulous glands. Thus the organs at risk (OARs) received dose increased. The radiotherapeutic toxicity are unavoidable. Some present studies show that the prone positioning of patients can improve dose homogeneity and reduce the dose distribution in OARs in patients with large and pendulous glands. Chinese women have relatively small breasts, the advantages of those have not been established. Therefore, investigators compared the parameters between supine and prone positions for whole breast irradiation after conserving surgery.

NCT ID: NCT05608980 Recruiting - Blepharitis Clinical Trials

0.01% Hypochlorous Acid in the Treatment of Blepharitis

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This is a multi-center, multidisciplinary, open-label, randomized controlled prospective clinical study.

NCT ID: NCT05608759 Recruiting - Surgery Clinical Trials

Exercise Prehabilitation for Patients With NSCLC Before Surgery

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

To explore the safety and compliance of a wearable telemedicine device that can receive basic vital signs in real time, and its active supervision mode with real-time adjustment of exercise prescription for preoperative prehabilitation exercises in patients at home; and to evaluate the effectiveness of preoperative prehabilitation exercises in a telemedicine active supervision mode in patients undergoing thoracoscopic lung tumour resection, taking into account the patient's cardiopulmonary exercise test, postoperative complications and quality of life scores.